Early Life Exposures Among Children With Sickle Cell Disease
Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · May 11, 2022
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Early Life Exposures Among Children with Sickle Cell Disease," is studying how various early life experiences, like childhood challenges and factors related to health and nutrition, can affect children with sickle cell disease. The goal is to understand how these experiences influence their mental well-being and lifestyle choices, ultimately aiming to improve their health outcomes.
To participate in this study, mothers of infants diagnosed with sickle cell disease who live in or near Birmingham, Alabama, may be eligible. The study is currently not recruiting participants, but once it begins, mothers will have the chance to engage in discussions and activities designed to help their children develop resilience and healthier habits. It's important to note that mothers taking certain medications that can harm a developing baby or those with limited internet access will not be able to participate. This research could provide valuable insights into supporting children with sickle cell disease and their families.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • mother of infant with sickle cell disease
- • resides within the city of Birmingham, Alabama or in close proximity
- Exclusion Criteria:
- • prescribed teratogenic medications
- • no/limited internet access
About University Of Alabama At Birmingham
The University of Alabama at Birmingham (UAB) is a prominent academic institution and research hub dedicated to advancing healthcare through innovative clinical trials. Renowned for its commitment to medical discovery and education, UAB conducts cutting-edge research across a wide array of disciplines, including oncology, cardiology, neurology, and public health. With a robust infrastructure for clinical research, UAB fosters collaboration among interdisciplinary teams, leveraging state-of-the-art facilities and resources to enhance the translation of scientific findings into effective treatments and interventions. As a leader in clinical research, UAB aims to improve patient outcomes and contribute to the broader medical community through rigorous trial design and implementation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Patients applied
Trial Officials
Brandi M Pernell, DNP, MSPH
Principal Investigator
University of Alabama at Birmingham
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials